Abstract: The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.
Type:
Grant
Filed:
January 29, 2020
Date of Patent:
February 18, 2025
Assignees:
THE ASAN FOUNDATION, EDISBIOTECH CO., LTD., UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
Inventors:
Seung-Jae Myung, Eun-Ju Do, Jayoung Kang, Hye-Nam Son, Hyori Kim, A-Neum Lee, Yeong Hui Cho
Abstract: The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.
Type:
Application
Filed:
January 29, 2020
Publication date:
March 24, 2022
Applicants:
THE ASAN FOUNDATION, EDISBIOTECH CO., LTD., UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
Inventors:
Seung-Jae MYUNG, Eun-Ju DO, Jayoung KANG, Hye-Nam SON, Hyori KIM, A-Neum LEE, Yeong Hui CHO